US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that China's National Medical Products Administration has approved Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) for use in males aged 9 to 26.
This is the first time an HPV vaccine has been authorised for use in males in China.
Gardasil is now indicated to prevent certain HPV-related cancers and diseases, including anal cancer, in males within this age group. The vaccine was previously approved for use in females in China.
Gardasil is a quadrivalent vaccine that protects against human papillomavirus types 6, 11, 16 and 18.
This approval expands the use of Gardasil in China and provides broader protection against HPV-related diseases in the country.
Valneva secures UK approval for world's first chikungunya vaccine
Anivive Lifesciences receives USD20m in funding from Leonid Capital Partners
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
hVIVO signs LOI for landmark Phase 3 whooping cough vaccine trial with ILiAD Biotechnologies
Abyssinia Biosciences signs collaborative agreement with Cordance Medical
hVIVO completes pilot study for hMPV challenge model
Merck's Gardasil approved for males in China
Brii Bio acquires BRII-179 IP rights
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
Orexo partners with Abera to develop nasal powder vaccines
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Sanofi's combination vaccine candidates for flu and COVID-19 get Fast Track Designation
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m